Barinthus Biotherapeutics plc Cash Flow Conversion Efficiency
Barinthus Biotherapeutics plc cash flow conversion efficiency. Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Barinthus Biotherapeutics plc (2019–2024)
Cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Barinthus Biotherapeutics plc share price for real-time trading data and today's change.
Barinthus Biotherapeutics plc Cash Flow Conversion Ratio Explained
Barinthus Biotherapeutics plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency. Also see Barinthus Biotherapeutics plc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Salomon A Angel Ltd
TA:ANGL
|
0.071x |
|
ENERGIA IN.Y DES. EO 025
F:F63
|
N/A |
|
Ai-Media Technologies Ltd
AU:AIM
|
0.037x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.165x |
|
Yuhwa Securities Co Ltd
KO:003465
|
0.183x |
|
WIIK Public Company Limited
BK:WIIK
|
0.009x |
|
Serinus Energy Inc.
WAR:SEN
|
0.002x |
|
AppSpotr AB
ST:APTR
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. Review Barinthus Biotherapeutics plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more